Fatigue in Primary Sjögren's Syndrome: Clinical, Laboratory, Psychometric, and Biologic Associations

Arthritis Care and Research

Volumn 68, Issue 1, 2016, Pages 123-131

  Karageorgas, Theofanis ^a   Fragioudaki, Sofia ^a   Nezos, Adrianos ^a   Karaiskos, Dimitrios ^a   Moutsopoulos, Haralampos M ^a   Mavragani, Clio P ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; HYDROXYCHLOROQUINE; INDOLEAMINE 2,3 DIOXYGENASE; MESSENGER RNA; PILOCARPINE; RITUXIMAB; STEROID; AUTOANTIBODY; BIOLOGICAL MARKER; INDOLEAMINE 2,3-DIOXYGENASE 1, HUMAN; STEROID 21 MONOOXYGENASE; TNFSF13B PROTEIN, HUMAN;

ADULT; ANTIBODY BLOOD LEVEL; ANXIETY; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; FATIGUE; FEMALE; FIBROMYALGIA; FUNCTIONAL ASSESSMENT; GENE; GENE EXPRESSION; HUMAN; IDO 1 GENE; MAJOR CLINICAL STUDY; MALE; MYALGIA; NEUROSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PSYCHOMETRY; SJOEGREN SYNDROME; SLEEP DISORDER; AGED; ANXIETY DISORDERS; B LYMPHOCYTE; BLOOD; CASE CONTROL STUDY; CHI SQUARE DISTRIBUTION; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PREDICTIVE VALUE; PSYCHOLOGY; QUESTIONNAIRE; REAL TIME POLYMERASE CHAIN REACTION; SEROLOGY; SJOGREN'S SYNDROME;

AGED; ANXIETY DISORDERS; AUTOANTIBODIES; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; BIOMARKERS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; DEPRESSION; FATIGUE; FEMALE; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PSYCHOMETRICS; REAL-TIME POLYMERASE CHAIN REACTION; SEROLOGIC TESTS; SJOGREN'S SYNDROME; STEROID 21-HYDROXYLASE; SURVEYS AND QUESTIONNAIRES;

EID: 84956607866     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22720     Document Type: Article

References (52)

1. Mavragani CP, Moutsopoulos HM., The geoepidemiology of Sjögren's syndrome. Autoimmun Rev 2010; 9: A305-10.
2. Mengshoel AM, Norheim KB, Omdal R., Primary Sjögren's syndrome: Fatigue is an ever-present, fluctuating, and uncontrollable lack of energy. Arthritis Care Res (Hoboken) 2014; 66: 1227-32.
3. Haldorsen K, Bjelland I, Bolstad AI, Jonsson R, Brun JG., A five-year prospective study of fatigue in primary Sjögren's syndrome. Arthritis Res Ther 2011; 13: R167.
4. Theander L, Strombeck B, Mandl T, Theander E., Sleepiness or fatigue? Can we detect treatable causes of tiredness in primary Sjögren's syndrome? Rheumatology (Oxford) 2010; 49: 1177-83.
5. Segal B, Thomas W, Rogers T, Leon JM, Hughes P, Patel D, et al., Prevalence, severity, and predictors of fatigue in subjects with primary Sjögren's syndrome. Arthritis Rheum 2008; 59: 1780-7.
6. Iannuccelli C, Spinelli FR, Guzzo MP, Priori R, Conti F, Ceccarelli F, et al., Fatigue and widespread pain in systemic lupus erythematosus and Sjögren's syndrome: Symptoms of the inflammatory disease or associated fibromyalgia? Clin Exp Rheumatol 2012; 30 Suppl 74: 117-21.
7. Afari N, Buchwald D., Chronic fatigue syndrome: A review. Am J Psychiatry 2003; 160: 221-36.
8. Champey J, Corruble E, Gottenberg JE, Buhl C, Meyer T, Caudmont C, et al., Quality of life and psychological status in patients with primary Sjögren's syndrome and sicca symptoms without autoimmune features. Arthritis Rheum 2006; 55: 451-7.
9. Strombeck B, Ekdahl C, Manthorpe R, Jacobsson LT., Physical capacity in women with primary Sjögren's syndrome: A controlled study. Arthritis Rheum 2003; 49: 681-8.
10. Van Leeuwen N, Bossema ER, Knoop H, Kruize AA, Bootsma H, Bijlsma JW, et al., Psychological profiles in patients with Sjögren's syndrome related to fatigue: A cluster analysis. Rheumatology (Oxford) 2015; 54: 776-83.
11. Karaiskos D, Mavragani CP, Sinno MH, Dechelotte P, Zintzaras E, Skopouli FN, et al., Psychopathological and personality features in primary Sjögren's syndrome-associations with autoantibodies to neuropeptides. Rheumatology (Oxford) 2010; 49: 1762-9.
12. Mavragani CP, Crow MK., Activation of the type I interferon pathway in primary Sjögren's syndrome. J Autoimmun 2010; 35: 225-31.
13. Nguyen CQ, Peck AB., The interferon-signature of Sjögren's syndrome: how unique biomarkers can identify underlying inflammatory and immunopathological mechanisms of specific diseases. Front Immunol 2013; 4: 142.
14. Hall JC, Casciola-Rosen L, Berger AE, Kapsogeorgou EK, Cheadle C, Tzioufas AG, et al., Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases. Proc Natl Acad Sci U S A 2012; 109: 17609-14.
15. Nezos A, Gravani F, Tassidou A, Kapsogeorgou EK, Voulgarelis M, Koutsilieris M, et al., Type I and II interferon signatures in Sjögren's syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjögren's related lymphomagenesis. J Autoimmun 2015; 63: 47-58.
16. Udina M, Castellvi P, Moreno-Espana J, Navines R, Valdes M, Forns X, et al., Interferon-induced depression in chronic hepatitis C: A systematic review and meta-analysis. J Clin Psychiatry 2012; 73: 1128-38.
17. Nashan D, Reuter K, Mohr P, Agarwala SS., Understanding and managing interferon-α-related fatigue in patients with melanoma. Melanoma Res 2012; 22: 415-23.
18. Fung FY, Li M, Breunis H, Timilshina N, Minden MD, Alibhai SM., Correlation between cytokine levels and changes in fatigue and quality of life in patients with acute myeloid leukemia. Leuk Res 2013; 37: 274-9.
19. Bellmann-Weiler R, Schroecksnadel K, Holzer C, Larcher C, Fuchs D, Weiss G., IFN-γ mediated pathways in patients with fatigue and chronic active Epstein Barr virus-infection. J Affect Disord 2008; 108: 171-6.
20. Murakami Y, Hoshi M, Imamura Y, Arioka Y, Yamamoto Y, Saito K., Remarkable role of indoleamine 2,3-dioxygenase and tryptophan metabolites in infectious diseases: Potential role in macrophage-mediated inflammatory diseases. Mediators Inflamm 2013; 2013: 391984.
21. Wichers MC, Maes M., The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-α-induced depression. J Psychiatry Neurosci 2004; 29: 11-7.
22. Mavragani CP, Fragoulis GE, Moutsopoulos HM,. Endocrine alterations in primary Sjögren's syndrome: An overview. J Autoimmun 2012; 39: 354-8.
23. Mavragani CP, Schini M, Gravani F, Kaltsas G, Moutsopoulos HM., Brief report: Adrenal autoimmunity in primary Sjögren's syndrome. Arthritis Rheum 2012; 64: 4066-71.
24. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al., Classification criteria for Sjögren's syndrome: A revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 554-8.
25. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al., The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: Report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33: 160-72.
26. Seror R, Theander E, Brun JG, Ramos-Casals M, Valim V, Dorner T, et al., Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Ann Rheum Dis 2015; 74: 859-66.
27. Zung WW., A self-rating depression scale. Arch Gen Psychiatry 1965; 12: 63-70.
28. Spielberger CD, Luchene RE., Manual for the State-Trait Anxiety Inventory (STAI). Palo Alto (CA): Consulting Psychologists Press; 1970.
29. Eysenck HJ., Manual of the EPQ. London: Stoughton Educational; 1975.
30. Soldatos CR, Dikeos DG, Paparrigopoulos TJ., Athens Insomnia Scale: Validation of an instrument based on ICD-10 criteria. J Psychosom Res 2000; 48: 555-60.
31. Stalikas A., Psychometric tools in Greece. Athens, Greece: Ellinika Grammata; 2002.
32. Muszalik M, Kedziora-Kornatowska K, Kornatowski T., Functional assessment and health-related quality of life (HRQOL) of elderly patients on the basis of the Functional Assessment of Chronic Illness Therapy (FACIT)-F questionnaire. Arch Gerontol Geriatr 2009; 49: 404-8.
33. Butt Z, Lai JS, Rao D, Heinemann AW, Bill A, Cella D., Measurement of fatigue in cancer, stroke, and HIV using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) scale. J Psychosom Res 2013; 74: 64-8.
34. Mease PJ., Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res (Hoboken) 2011; 63 Suppl 11: S64-85.
35. Hewlett S, Dures E, Almeida C., Measures of fatigue: Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional Questionnaire (BRAF MDQ), Bristol Rheumatoid Arthritis Fatigue Numerical Rating Scales (BRAF NRS) for severity, effect, and coping, Chalder Fatigue Questionnaire (CFQ), Checklist Individual Strength (CIS20R and CIS8R), Fatigue Severity Scale (FSS), Functional Assessment Chronic Illness Therapy (Fatigue) (FACIT-F), Multi-Dimensional Assessment of Fatigue (MAF), Multi-Dimensional Fatigue Inventory (MFI), Pediatric Quality Of Life (PedsQL) Multi-Dimensional Fatigue Scale, Profile of Fatigue (ProF), Short Form 36 Vitality Subscale (SF-36 VT), and Visual Analog Scales (VAS). Arthritis Care Res (Hoboken) 2011; 63 Suppl 11: S263-86.
36. Sampaio CG, Schrag A., Rating scales in Parkinson's disease: Clinical practice and research. New York: Oxford University Press; 2012.
37. Kirou KA, Lee C, George S, Louca K, Papagiannis IG, Peterson MG, et al., Coordinate overexpression of interferon-α-induced genes in systemic lupus erythematosus. Arthritis Rheum 2004; 50: 3958-67.
38. Westhoff G, Dorner T, Zink A., Fatigue and depression predict physician visits and work disability in women with primary Sjögren's syndrome: Results from a cohort study. Rheumatology (Oxford) 2012; 51: 262-9.
39. Hackett KL, Newton JL, Frith J, Elliott C, Lendrem D, Foggo H, et al., Impaired functional status in primary Sjögren's syndrome. Arthritis Care Res (Hoboken) 2012; 64: 1760-4.
40. Lendrem D, Mitchell S, McMeekin P, Bowman S, Price E, Pease CT, et al., Health-related utility values of patients with primary Sjögren's syndrome and its predictors. Ann Rheum Dis 2014; 73: 1362-8.
41. Hartkamp A, Geenen R, Bijl M, Kruize AA, Godaert GL, Derksen RH., Serum cytokine levels related to multiple dimensions of fatigue in patients with primary Sjögren's syndrome. Ann Rheum Dis 2004; 63: 1335-7.
42. Priori R, Iannuccelli C, Alessandri C, Modesti M, Antonazzo B, Di Lollo AC, et al., Fatigue in Sjögren's syndrome: Relationship with fibromyalgia, clinical and biologic features. Clin Exp Rheumatol 2010; 28 Suppl 63: S82-6.
43. Bax HI, Vriesendorp TM, Kallenberg CG, Kalk WW., Fatigue and immune activity in Sjögren's syndrome [letter]. Ann Rheum Dis 2002; 61: 284.
44. Gudbjornsson B, Broman JE, Hetta J, Hallgren R., Sleep disturbances in patients with primary Sjögren's syndrome. Br J Rheumatol 1993; 32: 1072-6.
45. Barendregt PJ, Visser MR, Smets EM, Tulen JH, van den Meiracker AH, Boomsma F, et al., Fatigue in primary Sjögren's syndrome. Ann Rheum Dis 1998; 57: 291-5.
46. Karaiskos D, Mavragani CP, Makaroni S, Zinzaras E, Voulgarelis M, Rabavilas A, et al., Stress, coping strategies and social support in patients with primary Sjögren's syndrome prior to disease onset: A retrospective case-control study. Ann Rheum Dis 2009; 68: 40-6.
47. Ng WF, Bowman SJ., Primary Sjögren's syndrome: too dry and too tired. Rheumatology (Oxford) 2010; 49: 844-53.
48. Dass S, Bowman SJ, Vital EM, Ikeda K, Pease CT, Hamburger J, et al., Reduction of fatigue in Sjögren's syndrome with rituximab: Results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 2008; 67: 1541-4.
49. Hartkamp A, Geenen R, Kruize AA, Bossema ER, Godaert GL, Bootsma H, et al., Serum dehydroepiandrosterone sulphate levels and laboratory and clinical parameters indicating expression of disease are not associated with fatigue, well-being and functioning in patients with primary Sjögren's syndrome. Clin Exp Rheumatol 2011; 29: 318-21.
50. Sacre K, Criswell LA, McCune JM., Hydroxychloroquine is associated with impaired interferon-α and tumor necrosis factor-α production by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Res Ther 2012; 14: R155.
51. Van den Borne BE, Dijkmans BA, de Rooij HH, le Cessie S, Verweij CL., Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-α, interleukin 6, and interferon-γ production by peripheral blood mononuclear cells. J Rheumatol 1997; 24: 55-60.
52. Mumcu G, Bicakcigil M, Yilmaz N, Ozay H, Karacayli U, Cimilli H, et al., Salivary and serum B-cell activating factor (BAFF) levels after hydroxychloroquine treatment in primary Sjögren's syndrome. Oral Health Prev Dent 2013; 11: 229-34.